Aptinyx
Evanston
About Aptinyx
Aptinyx Inc. is a biopharmaceutical company discovering and developing innovative therapies for challenging disorders of the brain and nervous system. Aptinyx has a proven platform for discovering proprietary compounds that work through a novel mechanism: modulation of the NMDA receptor to enhance pathways involved with nerve cell communication. This mechanism has applicability across a number of CNS disorders. Our goal is to rapidly advance our most promising drug candidates into clinical development for indications with high unmet medical need.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Delisted
- Employees: 51 – 100
- Estimated revenue: Less than $1M
- Total funding: $273.9M
- Funding stage: IPO
- Last round: Grant (Nov 2022)
- Ticker: nasdaq:APTX
- Website: aptinyx.com
- Phone: (847)871-0377
Industries & Categories
Biopharma, Biotechnology, Health Care, Medical
Social Profiles
Canonical: https://fsome.com/organization/aptinyx-47792 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.